Highlights
1 patent
About
Unlocking the Promise of Immune Checkpoint Inhibitors
4C Biomed combines cutting-edge science, real-world clinical insights and unique autologous cell systems (i.e. cancer and immune cells from the same patient) to drive the research and development of immuno-oncology therapies. Its lead drug is an IND-ready asset and is planned to enter clinical Phase I in 2026.
4C Biomed’s technology leverages a uniquely sensitive, immunological-based screening platform, which not only identifies novel immuno-oncology targets but also promises to accelerate the journey from discovery to clinical application.
Identity
| Name | 4C Biomed |
|---|---|
| Slug | 4c-biomed |
| Type / kind | startup |
| Source _id | I9HARjQF5otmlJD7xWv0oETmwNgLjC6EzFoHbPp20zuFWqzq01jvW4 |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Netanya |
| HQ address | Ha-Melakha St 5, Netanya, Israel |
Web & social
| Website | https://4cbiomed.com/ |
|---|---|
| https://www.linkedin.com/company/28145356 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
cancer-therapyoncologyimmunotherapyimmunologydrug-discoverycancerdrug-developmentpharmaceuticals
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}